Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30509998 | 1.00 | POLB (0.44) | POLBSMN1; SMN2HDAC1HDAC2RET | |
| SCHEMBL25379660 | 0.88 | HDAC1 (0.48) | POLBSMN1; SMN2HDAC1HDAC2RET | |
| SCHEMBL25255433 | 0.87 | APLNR (0.42) | HDAC1HDAC2 | |
| SCHEMBL30561711 | 0.84 | BTK (0.44) | — | |
| SCHEMBL30510032 | 0.84 | BTK (0.44) | — | |
| SCHEMBL25378579 | 0.84 | BTK (0.44) | — | |
| SCHEMBL25259171 | 0.84 | BTK (0.44) | — | |
| SCHEMBL25376367 | 0.82 | POLB (0.47) | POLBJAK2JAK3PTK2TP53 | |
| SCHEMBL25259054 | 0.80 | RET (0.43) | POLBHDAC1HDAC2RETJAK2 | |
| SCHEMBL22778162 | 0.79 | HPGDS (0.49) | POLBSMN1; SMN2HDAC1HDAC2HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552772-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250115574-A1 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | VIB VZW (BE) | 2025-04-10 | — | — | US | disclosed |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2023122780-A9 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023122780-A9 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-20230278982-A1 | 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD | KU LEUVEN R&D (BE) | 2023-09-07 | — | — | US | disclosed |
| US-20230278982-A1 | 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD | KU LEUVEN R&D (BE) | 2023-09-07 | — | — | US | disclosed |
| US-20230278982-A1 | 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD | KU LEUVEN R&D (BE) | 2023-09-07 | — | — | US | disclosed |
| WO-2023122780-A2 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122780-A2 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552772-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | POLB 3112/4885SMN1; SMN2 1362/4885HDAC1 378/4885 |
| US-20230278982-A1 | 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | POLB 1804/4885SMN1; SMN2 3398/4885HDAC1 586/4885 |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | POLB 1804/4885SMN1; SMN2 3398/4885HDAC1 586/4885 |
| US-20250115574-A1 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | POLB 1804/4885SMN1; SMN2 3398/4885HDAC1 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.